Skip to main navigation
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Investors

Press Releases

Date
Latest Press Release

May 9, 2019

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

April 30, 2019

Eiger to Present at ChinaBio® Partnering Forum 2019

April 17, 2019

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

April 17, 2019

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

April 15, 2019

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

April 11, 2019

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

March 26, 2019

Eiger BioPharmaceuticals to Participate in Conferences in April

March 25, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

March 20, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

March 14, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

Eiger - Shareholder Tools

  • Print Page
  • Contact Us
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX

Contact Us

Eiger Logo

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX